Cell Therapy Coming of Age
Continuing Education Credits
Objectives
- Identify the types, mechanism of action, and applications of cell therapy currently approved by the FDA.
- Contrast CAR-T therapy against blood cancers from solid cancers.
- Interpret how gene editing technology enabled the success of cell therapy against sickle cell anemia.
- Summarize viral vector-based genetic engineering facilitated cell therapy for the correct SCID.
- Identify the pros and cons of cell therapy.
Course Outline
- Cell Therapy: An Overview
- Overview of Cell Therapy
- True or False: Cell therapy relies on tools in cell and gene engineering.
- True or False: Cell therapy is only for cancer treatment.
- Stem Cell Therapy After Chemotherapy
- Stem Cells
- Role of Stem Cell Therapy
- True or False: Stem cell transplantation can only be obtained from the bone marrow.
- True or False: Peripheral stem cell transplantation is primarily used to replenish blood-forming cells destroyed during chemotherapy for cancer patients.
- True or False: G-CSF is prescribed to chemotherapy patients before chemotherapy.
- Cell Therapy for Severe Combined Immunodeficiency
- Cell Therapy for Severe Combined Immunodeficiency
- True or False: SCID results from a single type of genetic mutation.
- True or False: The correct Artemis gene was inserted into stem cells of the patient using an HIV-derived viral vector. Patients will not be infected with HIV because the viral vector is genetically engineered to be incapable of replication.
- Genetically Engineered Stem Cells
- Genetically Engineered Stem Cells for Treatment of Sickle Cell Anemia
- Silencing BCL11A by Leveraging on DNA Repair Error
- Sickle Cell Treatment
- True or False: CRISPR/Cas9-mediated silencing of the BCL11A gene also silenced the hemoglobin gene.
- True or False: CRISPR/Cas9 gene silencing is the result of end joining mistakes made by the non-homologous end joining DNA repair pathway.
- T Cell Therapy Against Blood Cancers
- T Cell Therapy Against Blood Cancers
- FDA Approved CAR-T Therapies for Blood Cancers
- CAR-T Cell Therapy Steps
- Progress of CAR-T Therapy
- True or False: CAR-T therapy uses cancer antigen-engineered T cells to be infused back into the patient to treat cancer.
- True or False: The first CAR-T therapy received FDA approval in 2017.
- CAR-T Cell Therapy Against Brain Tumors
- CAR-T Cell Therapy Against Brain Tumors
- Role of CAR-T Therapy and Glioblastoma Multiforme Cells
- True or False: CAR-T cancer immunotherapy is a live drug.
- True or False: The breakthrough of IL13Rα2-CAR-T is its ability to cross the blood-brain barrier.
- Cell Therapy Treatment of Melanoma
- Cell Therapy Treatment of Melanoma via Amtagvi
- Cell Therapy Treatment of Melanoma via Amtagvi, continued
- True or False: Amtagvi (lifileucel) is a new CAR-T cancer immunotherapy.
- True or False: Lymphodepleting conditioning (LD) chemotherapy treatment provided to patients prior to lifileucel (Amtagvi) infusion aims at depleting immune cells that compete with the infused patient T cells.
- T Cell Receptor Therapy for Sarcoma
- T Cell Receptor Therapy for Sarcoma
- T Cell Receptor Therapy for Sarcoma, continued
- True or False: The newly approved TCR drug afami-cel treats a rare cancer called synovial sarcoma.
- True or False: MAGE-A4 is an antigen found only on synovial sarcoma cancer cells.
- References
- References
Additional Information
Level of Instruction: Intermediate to Advanced
Intended Audience: Medical laboratory scientists, medical laboratory technicians, molecular biologists, laboratory supervisors, and laboratory managers. This course is also appropriate for MLS and MLT students and pathology residents.
Author Information: Dr. Nancy Liu-Sullivan, PhD, served as a Senior Research Scientist with a specialty in cancer genomics and drug discovery prior to joining the biology faculty at the College of Staten Island (CSI), City University of New York (CUNY), teaching Immunology, Radiation Biology, and General Biology, in addition to mentoring students in cancer research. Dr. Liu-Sullivan is also the author of MediaLab’s CE courses titled "Hallmarks and Signaling of Cancer Cell" and "HLA and Cancer Immunotherapy".
The author has no
conflict of interest to disclose.
Reviewer Information: Dr. Ronit Slotky, PhD, MSc, CABP, is an associate professor of oncology at Hackensack Median Health School of Medicine and the Director of the Cell Therapies Manufacturing Facility at the Hackensack University Medical Center. She earned her PhD in Biology at the Technion, Israel, and her MSc in Biostatistics at Columbia University Mailman School of Public Health. She completed her post-doctorate at Columbia University Medical Center, studying proteins’ structure and function. Dr. Slotky has been working in the cellular therapy field for over 15 years and has published numerous scientific articles in the field. She is a board member and the chair of the Cellular Therapy Section Coordinating Committee for the Advanced Association of Blood and Biotherapies (AABB), and a member of the International Society of Cell & Gene Therapy (ISCT) Laboratory Practices committee, as well as the FACT Standards HCT Processing Subcommittee. Her current work and research efforts focus on improving cell processing methods and patient outcomes and providing education opportunities for clinicians and researchers.
Course Description: The course will cover topics focusing on a type of cell therapy designed to cure a specific disease. A general overview of cell therapy is included, followed by subsequent topics discussing stem cell therapy and combined gene+cell therapy for immune deficiency and blood disorders. Then, the focus shifts to cell therapy for the treatment of cancers.